Cetus And PCR

I would like to compliment Rex Dalton on his summary of the broad range of applications of GeneAmp polymerase chain reaction (PCR) technology (The Scientist, April 17, 1989, page 1). However, I most strongly disagree with the article's implication that Cetus Corp. has prevented scientists from conducting research using PCR technology or interfered with "freedom of scientific thought." Academic scientists the world over have rapidly adopted PCR as a tool in their research efforts. Scientists at C

Written byRoberta Fildes
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Academic scientists the world over have rapidly adopted PCR as a tool in their research efforts. Scientists at Cetus have collaborated with many university scientists, helping them to become proficient with PCR and to incorporate this profoundly useful technology into their scientific work. Nearly 400 papers already have been published citing PCR. These contributions to the literature clearly demonstrate that Cetus is not impeding scientific progress. The breadth and significance of these reports are a source of profound satisfaction to everyone at Cetus, especially to the scientists who have been responsible for the development and refinement of this core technology.

I realize that there has been some early confusion in the press about the commercial use of PCR. However, our experience in our PCR licensing and development program has been that most of the people who make inquiries understand and appreciate Cetus's position. Dalton already has shown that there is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies